Search for: "Mylan Pharmaceuticals Inc"
Results 1 - 20 of 116
Sorted by Relevance | Sort by Date
RSS Subscribe:  20 results  |  100 results
10 Jun 9:02 pm by Patent Docs
... Court for the Northern District of West Virginia awarding $1,011,712 in costs to Plaintiff-Appellee Daiichi Pharmaceutical Co., and remanded to the District Court for an apportionment determination of the awarded costs. Daiichi owns U.S. Patent No. ... the trade name Levaquin®. Seeking approval to market a generic version of levofloxacin, Defendants-Appellants Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. filed an Abbreviated New Drug Application (ANDA) with the FDA. In response to Mylan's ...
Patent Docs - http://patentdocs.typepad.com/patent_docs/
17 Dec, 2008 5:54 am by Donald Zuhn
... No. 4,687,777. The challenges to the '777 patent had been initiated by Defendants-Appellants Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., and UDL Laboratories, Inc. (Mylan) on the one hand, and Defendants-Appellants Alphapharm Pty., Inc. and Genpharm, Inc. (Alphapharm) on the other. Seeking approval to market a generic version of the antidiabetic agent, 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione, ...
Patent Docs - http://patentdocs.typepad.com/patent_docs/
9 Apr, 2008 8:49 pm by Donald Zuhn
By Donald Zuhn -- Last week, the Federal Circuit issued an opinion in Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc. In Mylan Laboratories, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006, owned by Plaintiff-Appellee Ortho-McNeil...
Patent Docs - http://patentdocs.typepad.com/patent_docs/
6 Apr, 2008 9:15 pm by Donald Zuhn
By Donald Zuhn -- Last week, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006 to encompass Plaintiff-Appellee Ortho-McNeil Pharmaceutical, Inc.'s epilepsy drug topiramate, and affirmed the District Court's decision to (1) permanently enjoin Defendants-Appellees Mylan...
Patent Docs - http://patentdocs.typepad.com/patent_docs/
6 Jan, 2008 10:28 am
... approval for rosuvastatin calcium tablets, which is the generic version of Crestor. According to the complaint, Mylan's position before the FDA is that AstraZeneca's patent for Crestor is invalid and ... virtually identical to its West Virginia filing. AstraZeneca Pharmaceuticals LP, et al. v. Mylan Pharmaceuticals Inc., Civil Action No. 1:07-CV-00805 ... litigation, Judge Keeley has denied the motion to dismiss filed by Eliot Disner in Mylan's legal malpractice lawsuit against him. Here is Judge Keeley's ...
West Virginia Business Litigation - http://www.wvbusinesslitigationblog.com/
23 Jun, 2008 11:55 am by Tom Lamb
... , is initiating a Class 1 nationwide recall of Digitek (digoxin tablets, USP, all strengths) for oral use. The products are distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a " ... : What does "Good Manufacturing Practices" (GMP) mean? GMP is a regulatory guideline imposed on all manufacturers of pharmaceuticals in order to ensure compliance with quality standards such as the pharmacopeia standards, the marketing authorisation and other applicable ...
Drug Injury Watch - http://www.drug-injury.com/druginjurycom/
18 Oct 5:42 pm by Gene Quinn
... discussing the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. Teva announced that it has filed a lawsuit against Mylan Pharmaceuticals, Inc., ... Inc. to delay generic competition to Solvay's branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than $400 million. "At a time [...]... Senate Bill Would Prevent Reverse Pharma PaymentsThe ...
IPWatchdog.com | Patent Copyright Trademark - http://www.ipwatchdog.com
30 Sep 11:07 am
... , even though diversity of citizenship does not exist. But PG argues that Mylan, which is a Pennsylvania corporation and is the parent of Mylan Pharmaceuticals, Inc., "has no standing to sue for or recover damages" because the plaintiffs' claims are " ... of all persons delivering the Documents to the Post-Gazette or Reporter-Defendants." (Emphasis added.) In a footnote, PG describes Mylan's decision to file in state court as a "cynical appeal to local interests [] manifested , for instance, in the ...
West Virginia Business Litigation - http://www.wvbusinesslitigationblog.com/
26 Jun, 2007 10:48 pm
... drugs. The experienced Medicaid fraud prosecutors of the Texas Attorney General's Office have announced such allegations against three pharmaceutical manufacturers for tens of millions of dollars in Medicaid fraud in Texas. For pharmaceutical products ... -a-Care, an industry whistleblower, disclosed the scheme. The pharma companies named by the Attorney General are: • Mylan Laboratories Inc. of Pennsylvania (with national subsidiaries Mylan Pharmaceuticals Inc. and UDL Laboratories Inc.) • Sandoz ...
Whistleblower Lawyer Blog - http://www.whistleblowerlawyerblog.com/
24 Oct, 2007 12:46 pm by Phil
... , 2007: Mylan Inc. (NYSE: MYL) today announced that it and its subsidiary Mylan Pharmaceuticals Inc. have entered into a patent license and settlement agreement with GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride (HCl) Extended-release ... to monetize on our first-to-file opportunities and continuing to meet our commitment to bring affordable pharmaceuticals to the consumers who need them, we are extremely pleased to have reached this agreement with GSK. This is especially gratifying as ...
Tags: Payments, Reverse
Philip Brooks' Patent Infringement Updates - http://infringement.blogs.com/philip_brooks_patent_infr/
7 Feb, 2008 9:00 am
... ("Federated"), and Health Care Service Corporation ("HCSC") (collectively "Plaintiffs") against Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc., Cambrex Corporation, and Gyma Laboratories ("Defendants") on state law claims - agreement ... restraint of trade; conspiracy in unreasonable restraint of trade; monopolization; and, attempted monopolization - in the Lorazepam active pharmaceutical ingredient ("API") market, Lorazepam tablet market and in the Clorazepate API and tablet markets. The ...
InsureReinsure.Com: The Insurance & Reinsurance Blog - http://www.insurereinsure.com/
24 Aug 9:10 am
... Post-Gazette, Sabatini, Boselovic, and several John Does in the Circuit Court of Monongalia County, West Virginia. Mylan Pharmaceuticals, Inc v. PG Publishing Co., Civil Action No. 09-C-592 (August 19, 2009). Here ... no such issues existed. But another paragraph suggests the real reason for the lawsuit: The sensationalized misuse of the Documents caused harm to Mylan and its shareholders, evidenced by substantial market volatility, a decrease in its stock price, and the resulting decrease in market ...
West Virginia Business Litigation - http://www.wvbusinesslitigationblog.com/
5 Dec, 2008 5:31 am by Donald Zuhn
By Mark Chael -- On December 2nd, Mylan, Inc. and Mylan Pharmaceuticals, Inc. announced that they had settled their dispute with Novartis Pharmaceuticals Corp., Novartis Corp., and Novartis International AG over a generic version of ... of about $470 million for the 12 months ending September 30, 2008. Novartis initiated the dispute in June of 2006, when it sued Mylan following Mylan's filing of an ANDA with a Paragraph IV certification seeking approval to market generic letrozole tablets prior to...
Patent Docs - http://patentdocs.typepad.com/patent_docs/
24 Oct, 2008 12:32 am by Phil
The following appeared yesterday, October 22, 2008, at Business Week: Mylan Inc. said Wednesday it has been accused of patent infringement by Novartis AG over Mylan's generic version of the Swiss company's Lescol capsules for treating high cholesterol. Pittsburgh-based Mylan ... this month in U.S. District Court in New Jersey accusing Mylan and its subsidiary, Mylan Pharmaceuticals Inc., of violating a patent. Mylan's generic version of Lescol is called Fluvastatin. Mylan said it ...
Philip Brooks' Patent Infringement Updates - http://infringement.blogs.com/philip_brooks_patent_infr/
24 Oct, 2008 11:37 am by Varun
Swiss-drug major Novartis has filed a lawsuit in the US District Court for the District of New Jersey against Mylan Pharmaceuticals Inc. for infringement of Orange Book listed US Patent No. 5,354,772 (the '772 patent) for Lescol capsules, generically known as Fluvastatin Sodium. The infringement suit is result of Mylan's submission of an abbreviated new drug application (ANDA) with paragraph IV certification for the Lescol capsules earlier in June 2008. Mylan ...
Patent Circle - http://patentcircle.blogspot.com/
20 Aug, 2007 1:30 pm
... , he "allowed Mylan to enter into the exclusive supply agreement with Profarmaco/GYMA [who were to supply Mylan with the "active pharmaceutical ingredients" for lorazepam and clorazepate for the generic versions of the drugs on an exclusive basis] without fully investigating the issues ... a class consisting of former BAR/BRI students, whom McGuireWoods represented, and West Publishing and Kaplan, Inc., one of West's marketing partners. Under the proposed settlement, West would pay $36 million and ...
West Virginia Business Litigation - http://www.wvbusinesslitigationblog.com/
1 Aug, 2006 8:38 am by David Fischer
... am surprised there is only one story about modafinil (according to a Google News search). According to MarketWatch: Mylan Laboratories Inc. (MYL) said Monday that the Federal Trade Commission is investigating the company's patent-litigation settlement related to ... U.S. Cephalon also entered separate agreements with Teva Pharmaceuticals USA Inc. (TEVA), Ranbaxy Pharmaceuticals Inc. and Barr Laboratories Inc. (BRL). According to Mylan Laboratories' quarterly report filed Friday with the Securities ...
Antitrust Review - http://www.antitrustreview.com
... year. The SEC's order is available here. The Perry settlement arose from the failed attempt by Mylan Laboratories, Inc. to acquire King Pharmaceuticals, Inc. in 2004. Perry had a significant ownership stake in King and stood to benefit from the merger, ... was not in Mylan's best interests. Thus, Perry had different, and possibly inconsistent, interests from those of Mylan's other stockholders. The issue of "empty voting" is part of a larger phenomenon identified by Professors Henry Hu and Bernard ...
The Harvard Law School Corporate Governance Blog - http://blogs.law.harvard.edu/corpgov
15 Jun, 2007 8:11 am by Jake Ward
... member of a class of compounds referred to as dihydropyridines. Active drug molecules, such as amlodipine, are frequently made into pharmaceutically-acceptable acid addition salts to improve their bioavailability. Amlodipine besylate is an acid addition salt form of amlodipine, ... the KSR ruling (See, e.g., Dystar Textilfarben GMBH & Co Deutschland KG v. C.H. Patrick, Co., et al., Alza Corporation v. Mylan Laboratories, Inc., et al., and Ormco Corporation, et al. v. Align Technology, Inc. etc).
ANTICIPATETHIS.com - http://anticipatethis.wordpress.com
8 Aug 1:43 am by Dr. Shezad Malik
A Texas law firm is targeting generic drug giant Mylan Inc., along with other pharmaceutical companies, in product liability lawsuits related to the manufacture of pain patches. The lawsuits involve the powerful painkiller fentanyl, which is applied ... at a time when the Food & Drug Administration has been looking into allegations of compliance problems at a separate Mylan plant in Morgantown, W.Va. The FDA probe was prompted by a July 26 story in the Pittsburgh Post-Gazette that described how ...
Dallas Fort Worth Injury Lawyer Blog - http://www.dallasfortworthinjurylawyer.com/
        Next >
Add to your RSS Reader Add to your Google Add to your My Yahoo Add to your My MSN Add to your My AOL Add to your Feedster Add to your Newsgator Add to your Bloglines Add to your NewsBurst Add to your Rojo Add to your Pluck